Potential therapeutic applications of phosphodiesterase inhibition in prostate cancer

World Journal of Urology

Volumn 31, Issue 2, 2013, Pages 325-330

  Hamilton, Thomas K ^a   Hu, Nianping ^a   Kolomitro, Klodiana ^a   Bell, Erin N ^a   Maurice, Donald H ^a   Graham, Charles H ^a   Siemens, D Robert ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

Drug resistance; Immunotherapy; Phosphodiesterase inhibitors; Phosphodiesterases

Indexed keywords

EID: 84876437421     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-012-0848-7     Document Type: Article

References (28)

1. Semenza GL (2002) HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol Med 8(4 suppl): S62-S67.
2. Movsas B, Chapman JD, Greenberg RE et al (2000) Increasing levels of hypoxia in prostate carcinoma correlate significantly with increasing clinical stage and patient age: and Eppendorf pO(2) study. Cancer 89: 2018-2024.
3. Gillet J-P, Gottesmon MM (2010) Multi-drug resistance in cancer. Methods Mol Biol 596: 47-76.
4. Frederiksen LJ, Siemens DR, Heaton JP et al (2003) Hypoxia induced resistance to doxorubicin in prostate cancer cells is inhibited by low concentrations of glyceryl trinitrate. J Urol 170: 1003-1007.
5. Matthews NE, Adams MA, Maxwell LR et al (2001) Nitric oxide-mediated regulation of chemosensitivity in cancer cells. J Natl Cancer Inst 93: 1879-1885.
6. Wartenberg M, Gronczynska S, Bekhite MM et al (2005) Regulation of the multidrug resistance transporter P-glycoprotein in multicellular prostate tumor spheroids by hyperthermia and reactive oxygen species. Int J Cancer 113: 229-240.
7. Siemens DR, Hu N, Sheikhi AK et al (2008) Hypoxia increases tumor cell shedding of MHC class I chain-related molecule: role of nitric oxide. Cancer Res 68: 4746-4753.
8. Barsoum IB, Hamilton TK, Li X, Cotechini T, Miles EA, Siemens DR, Graham CH (2011) A mechanism of hypoxia-induced immune escape in cancer cells. Cancer Res 71: 7433-7441.
9. Groh V, Wu J, Yee C, Spies T (2002) Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 419: 734-738.
10. Frederiksen LJ, Sullivan R, Maxwell LR et al (2007) Chemosensitization of cancer in vitro and in vivo by nitric oxide signaling. Clin Cancer Res 13(7): 2199-2206.
11. Bell EN, Tse MY, Frederiksen LJ et al (2007) Atrial natriuretic peptide attenuates hypoxia induced chemoresistance in prostate cancer cells. J Urol 177(2): 751-756.
12. Yasuda H, Nakayama K, Watanabe M et al (2006) Nitroglycerin treatment may enhance chemosensitivity to docetaxel and carboplatin in patients with lung adenocarcinoma. Clin Cancer Res 12(22): 6748-6757.
13. Siemens DR, Heaton JP, Adams MA et al (2009) Phase II study of nitric oxide donor for men with increasing prostate-specific antigen level after surgery or radiotherapy for prostate cancer. Urology 74(4): 878-883.
14. Soderling SH, Beavo JA (2000) Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions. Curr Opin Cell Biol 12(2): 174-179.
15. Bender AT, Beavo JA (2006) Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev 58(3): 488-520.
16. Abdollahi M, Chan TS, Subrahmanyam V et al (2003) Effects of phosphodiesterase 3, 4, 5 inhibitors on hepatocyte cAMP levels, glycogenolysis, gluconeogenesis and susceptibility to a mitochondrial toxin. Mol Cell Biochem 252(1-2): 205-211.
17. Sarfati M, Mateo V, Baudet S et al (2003) Sildenafil and vardenafil, types 5 and 6 phosphodiesterase inhibitors, induce caspase-dependent apoptosis of B-chronic lymphocytic leukemia cells. Blood 101(1): 265-269.
18. Zhu B, Vemavarapu L, Thompson WJ et al (2005) Suppression of cyclic GMP-specific phosphodiesterase 5 promotes apoptosis and inhibits growth in HT29 cells. J Cell Biochem 94(2): 336-350.
19. Qian C-N, Takahashi M, Kahnoski RJ, The BT (2003) Effect of sildenafil citrate on an orthotopic prostate cancer growth and metastasis model. J Urol 170: 994-997.
20. Das A, Durrant D, Mitchell C (2010) Sildenafil increases chemotherapeutic efficacy of doxorubicin in prostate cancer and ameliorates cardiac dysfunction. Proc Natl Acad Sci USA 107(42): 18202-18207.
21. Davis CW, Daly JW (1979) A simple direct assay of 3′, 5'-cyclic nucleotide phosphodiesterase activity based on the use of polyacrylamide-bononate affinity gel chromatography. J Cyclic Nucleotide Res 5(1): 65-74.
22. Tannock IF, de Wit R, Berry WR et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351: 1502-1512.
23. Petrylak DP, Tangen CM, Hussain MH et al (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351(15): 1513-1520.
24. Pienta KJ, Naik H, Lehr JE (1996) Effect of estramustine, etoposide, and taxol on prostate cancer cell growth in vitro and in vivo. Urology 48: 164-170.
25. Cengiz E, Karaca B, Kucukzeybek Y et al (2010) Overcoming drug resistance in hormone- and drug-refractory prostate cell line, PC-3 by docetaxel and gossypol combination. Mol Biol Rep 37: 1269-1277.
26. Wu JD, Higgins LM, Steinle A et al (2004) Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer. J Clin Invest 114: 560-568.
27. Holdenrieder S, Stieber P, Peterfi A et al (2006) Soluble MICA in malignant diseases. Int J Cancer 118: 684-687.
28. Marten A, Lilienfeld-Toal M, Buchler MW et al (2006) Soluble MIC is elevated in the serum of patients with pancreatic carcinoma diminishing γδ T cell cytotoxicity. Int J Cancer 119: 2359-2365.